Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

New England Journal of Medicine

Volumn 368, Issue 23, 2013, Pages 2169-2181

  Legendre, C M ^a   Licht, C ⁱ   Muus, P ^j   Greenbaum, L A ^k   Babu, S ^l   Bedrosian C Bingham, C ^m,n   Cohen, D J ^q   Delmas, Y ^c   Douglas, K ^o   Eitner, F ^t   Feldkamp, T ^u   Fouque, D ^d   Furman, R R ^r   Gaber, O ^r,s   Herthelius, M ^x   Hourmant, M ^e   Karpman, D ^y   Lebranchu, Y ^f   Mariat, C ^g   Menne, J ^v   Moulin, B ^h   Nurnberger J ^w   Ogawa, M ^m   Remuzzi, G ^z   Richard, T ^ab   Sberro Soussan, R ^a   Severino, B ^m   Sheerin, N S ^p   Trivelli, A ^aa   Zimmerhackl, L B ^ac   Goodship, T ^p   Loirat, C ^b   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE LYON   (France)

^e HÔTEL DIEU   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g HÔPITAL NORD   (France)

^h HÔPITAL CIVIL   (France)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^l Fort Wayne Medical Oncology and Hematology   (United States)

^m ALEXION PHARMACEUTICALS   (United States)

ⁿ ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^o BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q Department of Medicine   (United States)

^r WEILL CORNELL MEDICAL COLLEGE   (United States)

^s NEW YORK METHODIST HOSPITAL   (United States)

^t RWTH AACHEN UNIVERSITY   (Germany)

^u UNIVERSITY OF DUISBURG ESSEN   (Germany)

^v HANNOVER MEDICAL SCHOOL   (Germany)

^w HELIOS KLINIKEN SCHWERIN   (Germany)

^x KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^y LUND UNIVERSITY   (Sweden)

^z MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^aa G GASLINI INSTITUTE   (Italy)

^ab Alexion Pharma International   (Switzerland)

^ac NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB;

ADOLESCENT; ADULT; ARTICLE; ASYMPTOMATIC BACTERIURIA; CLINICAL ARTICLE; DIALYSIS; DRUG MECHANISM; FEMALE; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HYPERTENSION; INFLUENZA; KIDNEY INJURY; MALE; MALIGNANT HYPERTENSION; MENINGOCOCCOSIS; MULTICENTER STUDY; PERITONITIS; PHASE 2 CLINICAL TRIAL; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCLEROSIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; VEIN DISEASE; VENOUS SCLEROSIS;

EID: 84878589219     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1208981     Document Type: Article

References (35)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-87.
2. Zipfel PF. Thrombotic microangiopathies: new insights and new challenges. Curr Opinion Nephrol Hypertens 2010;4:372-8.
3. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009;9:729-40.
4. Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013;54:84-8.
5. Licht C, Pluthero FG, Ling L, et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009;114:4538-45.
6. Benz K, Amann K. Thrombotic microangiography: new insights. Curr Opin Nephrol Hypertens 2010;19:242-7.
7. Caprioli J, Noris M, Brioshi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-79.
8. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-59.
9. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60.
10. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:673-81.
11. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72.
12. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice: today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010;169:7-13.
13. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8:554-62.
14. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux- Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7:23-35.
15. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13:663-75.
16. Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;20:940-9.
17. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012;41:e115-e135.
18. Wilson C, Torpey N, Jacques B, et al. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011;58:109-12.
19. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64. [Erratum, Nat Biotechnol 2007;25:1488.]
20. Ariceta G, Arriyabalaga B, Aguirre M, et al. Eculizumab in the treatment of aHUS in infants. Am J Kidney Dis 2012;59:707-10.
21. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-syndrome. Am J Transplant 2009;11:2644-5.
22. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:544-6.
23. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010;362:1746-8.
24. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-57.
25. Zuber J, Quintrec ML, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12:3337-54.
26. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.
27. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
28. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117;6786-92.
29. Electronic Medicines Compendium. Soliris: summary of product characteristics (http://www.medicines.org.uk/emc/medicine/19966/SPC/soliris).
30. Soliris.net. U.S. prescribing information (http://soliris.net/sites/ default/files/assets/soliris-pi.pdf).
31. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTs13 assay. Br J Haematol 2005;129:93-100.
32. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med 2011:33:337-43.
33. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-72.
34. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010;89:903-4.
35. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1312-6.